EPHX1

Summary

EPHX1 (epoxide hydrolase 1, HGNC:3401) is a protein-coding gene on chromosome 1q42.12, encoding Epoxide hydrolase 1 (P07099). Biotransformation enzyme that catalyzes the hydrolysis of arene and aliphatic epoxides to less reactive and more water soluble dihydrodiols by the trans addition of water.

Epoxide hydrolase is a critical biotransformation enzyme that converts epoxides from the degradation of aromatic compounds to trans-dihydrodiols which can be conjugated and excreted from the body. Epoxide hydrolase functions in both the activation and detoxification of epoxides. Mutations in this gene cause preeclampsia, epoxide hydrolase deficiency or increased epoxide hydrolase activity. Alternatively spliced transcript variants encoding the same protein have been found for this gene.

Source: NCBI Gene 2052 — RefSeq curated summary.

At a glance

• Gene–disease (curated): hereditary lipodystrophy (Strong, GenCC) — +2 more curated relationships
• GWAS associations: 2
• Clinical variants (ClinVar): 145 total — 1 pathogenic, 1 likely-pathogenic
• Phenotypes (HPO): 2
• Druggable target: yes — 2 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_001136018

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:3401
Approved symbol	EPHX1
Name	epoxide hydrolase 1
Location	1q42.12
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000143819
Ensembl biotype	protein_coding
OMIM	132810
Entrez	2052

Gene structure

Transcript identifiers

Ensembl transcripts: 73 — 72 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000272167, ENST00000366837, ENST00000448202, ENST00000467015, ENST00000614058, ENST00000869467, ENST00000869468, ENST00000869469, ENST00000869470, ENST00000869471, ENST00000869472, ENST00000869473, ENST00000869474, ENST00000869475, ENST00000869476, ENST00000869477, ENST00000869478, ENST00000869479, ENST00000869480, ENST00000869481, ENST00000869482, ENST00000869483, ENST00000869484, ENST00000869485, ENST00000869486, ENST00000869487, ENST00000869488, ENST00000869489, ENST00000869490, ENST00000869491, ENST00000869492, ENST00000869493, ENST00000869494, ENST00000869495, ENST00000869496, ENST00000869497, ENST00000869498, ENST00000869499, ENST00000869500, ENST00000869501, ENST00000869502, ENST00000869503, ENST00000869504, ENST00000869505, ENST00000869506, ENST00000869507, ENST00000869508, ENST00000869509, ENST00000869510, ENST00000869511, ENST00000869512, ENST00000869513, ENST00000869514, ENST00000869515, ENST00000869516, ENST00000869517, ENST00000869518, ENST00000869519, ENST00000869520, ENST00000869521, ENST00000869522, ENST00000869523, ENST00000869524, ENST00000869525, ENST00000869526, ENST00000869527, ENST00000869528, ENST00000869529, ENST00000869530, ENST00000912789, ENST00000945636, ENST00000945637, ENST00000945638

RefSeq mRNA: 10 — MANE Select: NM_001136018 NM_000120, NM_001136018, NM_001291163, NM_001378426, NM_001378427, NM_001378428, NM_001378429, NM_001378430, NM_001378431, NM_001378432

CCDS: CCDS1547

Canonical transcript exons

ENST00000272167 — 9 exons

Exon	Start	End
ENSE00000962129	225831779	225831959
ENSE00000962130	225838654	225838881
ENSE00000962131	225839217	225839346
ENSE00000962134	225844498	225844623
ENSE00001128824	225842366	225842474
ENSE00001128829	225839829	225840037
ENSE00001146182	225828725	225828912
ENSE00001309449	225810124	225810169
ENSE00003730015	225845146	225845563

Expression profiles

Bgee: expression breadth ubiquitous, 276 present calls, max score 99.82.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 69.2091 / max 1458.7051, expressed in 1769 samples.

FANTOM5 promoters (8 alternative TSS)

Promoter ID	TPM avg	Samples expressed
8834	58.6112	1751
8833	6.3925	1648
8837	1.8187	39
8832	1.3410	947
8839	0.6999	382
8836	0.2343	15
8838	0.0818	17
8835	0.0297	10

Top tissues by expression

296 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right adrenal gland cortex	UBERON:0035827	99.82	gold quality
right adrenal gland	UBERON:0001233	99.79	gold quality
adrenal cortex	UBERON:0001235	99.77	gold quality
left adrenal gland	UBERON:0001234	99.76	gold quality
left adrenal gland cortex	UBERON:0035825	99.76	gold quality
adrenal gland	UBERON:0002369	99.54	gold quality
right lobe of liver	UBERON:0001114	99.50	gold quality
left ovary	UBERON:0002119	99.20	gold quality
right ovary	UBERON:0002118	99.15	gold quality
liver	UBERON:0002107	99.13	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	99.11	gold quality
right uterine tube	UBERON:0001302	99.10	gold quality
bronchial epithelial cell	CL:0002328	99.07	gold quality
epithelium of bronchus	UBERON:0002031	99.02	gold quality
bronchus	UBERON:0002185	99.00	gold quality
nasal cavity epithelium	UBERON:0005384	98.85	gold quality
body of pancreas	UBERON:0001150	98.71	gold quality
endocervix	UBERON:0000458	98.62	gold quality
omental fat pad	UBERON:0010414	98.59	gold quality
peritoneum	UBERON:0002358	98.58	gold quality
adipose tissue of abdominal region	UBERON:0007808	98.53	gold quality
left lobe of thyroid gland	UBERON:0001120	98.50	gold quality
right lobe of thyroid gland	UBERON:0001119	98.40	gold quality
adipose tissue	UBERON:0001013	98.35	gold quality
gall bladder	UBERON:0002110	98.34	gold quality
dorsal root ganglion	UBERON:0000044	98.31	gold quality
urethra	UBERON:0000057	98.22	gold quality
subcutaneous adipose tissue	UBERON:0002190	98.20	gold quality
trigeminal ganglion	UBERON:0001675	98.18	gold quality
trachea	UBERON:0003126	98.13	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 4.

Experiment	Marker?	Max mean expression
E-CURD-114	yes	54.44
E-ANND-3	yes	18.53
E-HCAD-4	yes	18.02
E-MTAB-8410	yes	9.07

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): CEBPA, ESR1, FOXA2, GATA4, HNF4A, MYC, NFE2L2, NR1I3, SFPQ, SP1, SP3

miRNA regulators (miRDB)

21 targeting EPHX1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-3151-5P	99.86	63.83	1069
HSA-MIR-4447	99.85	67.81	2900
HSA-MIR-6842-5P	99.80	67.54	1587
HSA-MIR-7110-5P	99.80	67.84	1712
HSA-MIR-3150A-3P	99.76	64.44	1640
HSA-MIR-6763-5P	99.76	64.68	1767
HSA-MIR-1249-5P	99.61	66.55	2049
HSA-MIR-6797-5P	99.61	66.55	2084
HSA-MIR-6752-5P	99.59	67.32	1243
HSA-MIR-6751-5P	99.56	64.99	1145
HSA-MIR-4472	99.56	66.08	1478
HSA-MIR-1207-5P	99.49	69.11	2983
HSA-MIR-6803-5P	99.19	63.90	1026
HSA-MIR-491-5P	99.13	65.98	1468
HSA-MIR-6887-5P	98.56	68.49	1295
HSA-MIR-6795-5P	98.52	68.51	1277
HSA-MIR-6515-5P	97.08	65.48	1219
HSA-MIR-6742-5P	96.32	64.01	869
HSA-MIR-6796-5P	95.37	66.08	1120

Literature-anchored findings (GeneRIF, showing 40)

• Common polymorphisms within EPHX1 do not appear to be important risk factors for Parkinson’s disease. (PMID:11692079)
• Polymorphisms in microsomal epoxide hydrolase is associated with ovarian cancer (PMID:11809533)
• polymorphisms were significantly associated with hepatitis C virus-related liver disease severity and hepatocellular carcinoma risk (PMID:12085365)
• evidence that microsomal epoxide hydrolase is a target for tamoxifen and that target proteins are implicated in cell lipid metabolism (PMID:12121132)
• Two exonic single nucleotide polymorphisms in the gene are jointly associated with preeclampsia. (PMID:12173035)
• Polymorphisms in microsomal epoxide hydrolase is associated with laryngeal cancer (PMID:12359356)
• Microsomal epoxide hydrolase variants are not associated with risk of breast neoplasms. (PMID:12496064)
• A significant increase in risk for neoplasia was observed for the low-activity mEH 113 His allele after adjustment for smoking (PMID:12552594)
• Polymorphism in EPHX1 might be associated with development of emphysematous changes in the lung. (PMID:12579334)
• polymorphisms in microsomal epoxide hydrolase is associated with esophageal tumorigenesis (PMID:12670526)
• polymorphisms in microsomal epoxide hydrolase associated with lung cancer risk (PMID:12915882)
• Tyr113His polymorphism is not associated with susceptibility to esophageal squamous cell carcinoma in a population of North China. (PMID:14669306)
• GATA-4 plays a transactivator role in the regulation of the transcription of the EPHX1 gene (PMID:14984931)
• EPHX1 expression is regulated by C/EBPalpha interacting with DNA-bound NF-Y (PMID:15150264)
• Exon 1 sequence promoter functions as the primary driver of EPHX1 expression in human tissues. (PMID:15465926)
• Results suggest that mEH “slow” genotypes increase the annual decline rate of lung function for subjects occupationally exposed to airborne endotoxin (PMID:15531751)
• In liver microsomes, no major differences were evident in the reaction rates generated among preparations representing the different EPHX1 alleles. (PMID:15535985)
• The slow 113His EPHX1 allele tends to be more frequent among the patients with lung cancer than in normal controls (PMID:15640939)
• results suggest that codon 113 polymorphism may modify risk for development of chronic obstructive pulmonary disease (PMID:15702235)
• Nuclear genetic polymorphisms related to oxidative stress or apoptosis may modify the age at onset of Leber’s hereditary optic neuropathy (LHON). (PMID:15838728)
• Significant differences were not found for the risk of colon cancer and smoking for mEH genotype polymorphisms Y113H and H139R. (PMID:15894702)
• individuals exposed to tobacco carcinogens were at increased risk of colorectal cancer and that overall risk is related to microsomal epoxide hydrolase and CYP2C9 genotype (PMID:15924351)
• the mEH His113His genotype can differentiate the association between smoking, areca chewing, and esophageal squamous-cell-carcinoma (PMID:16029924)
• Results suggest that polymorphisms at codon 113 and 139 in microsomal epoxide hydrolase do not play a significant role in susceptibility to the mutagenic effects of vinyl chloride occupational exposure. (PMID:16201204)
• The present study demonstrates a significant increase in mEH expression in the AD hippocampus, a region showing abundant neuropathology in AD. (PMID:16630050)
• EPHX1 gene polymorphisms is associated with sporadic distal colorectal adenomas (PMID:17082176)
• Low EPHX1 activity genotype may be protective for people occupationally exposed to asbestos. (PMID:17159790)
• Genetic polymorphisms in HOX-1 and mEPH genes are associated with the development of COPD in Southwest China (PMID:17203192)
• Genetic variability in exon 3 and 4 of EPHX may be a risk factor for pre-eclampsia. (PMID:17212663)
• the expression level of mEH is as important as genetic polymorphism in non-small cell lung cancer; could be involved in drug resistance and prognosis of patients (PMID:17273734)
• Polymorphic variants in EPHX1 are associated with both emphysema distribution and COPD susceptibility (PMID:17363767)
• EPHX1 genotype was not associated with risk of myocardial infarction, regardless of smoking status, suggesting EPHX1 does not play a significant role in the development of coronary heart disease. (PMID:17380322)
• EPHX1 genotypes modified the association between maternal passive smoking and infant birth weight, which is suggestive of possible gene-environment interaction. (PMID:17526865)
• In conclusion, 105V/114V alleles of GSTP1 and 113H/139H alleles of mEPHX and the combination of genotypes with same alleles associated with imbalanced oxidative stress and lung function in patients. (PMID:17532303)
• Finds neither EPHX1 exon 3 nor EPHX1 exon 4 polymorphisms are associated with an increased risk of COPD. Finds also that none of the EPHX1 haplotypes are associated with an increased risk of any COPD phenotype. (PMID:17564249)
• genetic variation of the detoxification enzymes EPHX1 and GSTP1 do not increase the risks of orofacial clefting, nor do they influence the risks associated with maternal smoking. (PMID:17608547)
• EPHX1 polymorphism is not associated with the risk of head and neck cancer (PMID:17611777)
• The interaction between the polymorphisms of mEH gene and the indoor air pollution plays an important role in the carcinogenesis of lung. (PMID:17767854)
• The biotransformation enzymes GSTM1, GSTP1 and EPHX1 may modify the effect of dietary factors on the risk of developing colorectal carcinoma and adenoma. (PMID:18093316)
• our study demonstrated that exon 3 His genotype of the mEH are more prone to the risk of sporadic bladder cancer in North India (PMID:18200441)

Cross-species orthologs

41 orthologs

Organism	Symbol	Gene ID
danio_rerio	ephx1	ENSDARG00000042854
mus_musculus	Ephx1	ENSMUSG00000038776
rattus_norvegicus	Ephx1	ENSRNOG00000003515
drosophila_melanogaster	Jheh1	FBGN0010053
drosophila_melanogaster	Jheh2	FBGN0034405
drosophila_melanogaster	Jheh3	FBGN0034406
caenorhabditis_elegans		WBGENE00007807
caenorhabditis_elegans		WBGENE00007864
caenorhabditis_elegans		WBGENE00007866
caenorhabditis_elegans		WBGENE00007867
caenorhabditis_elegans		WBGENE00007872
caenorhabditis_elegans		WBGENE00007873
caenorhabditis_elegans		WBGENE00007875
caenorhabditis_elegans		WBGENE00007876
caenorhabditis_elegans		WBGENE00008922
caenorhabditis_elegans		WBGENE00010103
caenorhabditis_elegans		WBGENE00010123
caenorhabditis_elegans		WBGENE00010124
caenorhabditis_elegans		WBGENE00010125
caenorhabditis_elegans		WBGENE00010126
caenorhabditis_elegans		WBGENE00010127
caenorhabditis_elegans		WBGENE00010128
caenorhabditis_elegans		WBGENE00010657
caenorhabditis_elegans		WBGENE00010658
caenorhabditis_elegans		WBGENE00010659
caenorhabditis_elegans		WBGENE00010660
caenorhabditis_elegans		WBGENE00010745
caenorhabditis_elegans		WBGENE00010746
caenorhabditis_elegans		WBGENE00010747
caenorhabditis_elegans		WBGENE00010748
caenorhabditis_elegans		WBGENE00010749
caenorhabditis_elegans		WBGENE00010750
caenorhabditis_elegans		WBGENE00011487
caenorhabditis_elegans		WBGENE00011844
caenorhabditis_elegans		WBGENE00014132
caenorhabditis_elegans		WBGENE00014135
caenorhabditis_elegans		WBGENE00014136
caenorhabditis_elegans		WBGENE00014194
caenorhabditis_elegans		WBGENE00020909
caenorhabditis_elegans		WBGENE00045379
caenorhabditis_elegans		WBGENE00269425

Protein

Protein identifiers

Epoxide hydrolase 1 — P07099 (reviewed: P07099)

Alternative names: Epoxide hydratase, Microsomal epoxide hydrolase

All UniProt accessions (3): P07099, B1AQP8, R4SBI6

UniProt curated annotations — full annotation on UniProt →

Function. Biotransformation enzyme that catalyzes the hydrolysis of arene and aliphatic epoxides to less reactive and more water soluble dihydrodiols by the trans addition of water. Plays a role in the metabolism of endogenous lipids such as epoxide-containing fatty acids. Metabolizes the abundant endocannabinoid 2-arachidonoylglycerol (2-AG) to free arachidonic acid (AA) and glycerol. Binds 20(S)-hydroxycholesterol (20(S)-OHC).

Subcellular location. Microsome membrane. Endoplasmic reticulum membrane.

Tissue specificity. Found in liver.

Disease relevance. In some populations, the high activity haplotype tyr113/his139 is overrepresented among women suffering from pregnancy-induced hypertension (pre-eclampsia) when compared with healthy controls. Variations in EPHX1 gene non-coding regions have been observed in a patient with hypercholanemia. The pathogenicity of these variants has not been confirmed.

Activity regulation. Inhibited by 10-hydroxystearamide and methoxy-arachidonyl fluorophosphate.

Similarity. Belongs to the peptidase S33 family.

RefSeq proteins (10): NP_000111, NP_001129490, NP_001278092, NP_001365355, NP_001365356, NP_001365357, NP_001365358, NP_001365359, NP_001365360, NP_001365361 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000073	AB_hydrolase_1	Domain
IPR000639	Epox_hydrolase-like	Family
IPR016292	Epoxide_hydrolase	Family
IPR029058	AB_hydrolase_fold	Homologous_superfamily

Pfam: PF00561

Enzyme classification (BRENDA):

• EC 3.3.2.9 — microsomal epoxide hydrolase (BRENDA: 39 organisms, 247 substrates, 179 inhibitors, 46 Km, 9 kcat entries)

Substrate kinetics (BRENDA)

29 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
CIS-STILBENE OXIDE	0.0024–0.141	5
JUVENILE HORMONE III	0.0003–0.0138	3
2-(4-METHOXYPHENYL)-N-METHYL-N-[(3-METHYLOXETAN-	0.139–0.684	2
4-METHYL-2-OXO-2H-CHROMEN-7-YL OXIRAN-2-YLMETHYL	0.012–0.022	2
CYANO(6-METHOXY-NAPHTHALEN-2-YL)METHYL GLYCIDYL	0.0023–0.0038	2
STYRENE OXIDE	0.53–0.67	2
[3-[4-([((3-METHYLOXETAN-3-YL)METHYL)AMINO]METHY	0.027–0.067	2
[3-[4-([METHYL[(3-METHYLOXETAN-3-YL)METHYL]AMINO	0.028–0.089	2
[5-(4-METHOXYPHENYL)-1,3,4-OXADIAZOL-2-YL][3-[4-	0.05–0.051	2
[5-(4-METHOXYPHENYL)-1,3,4-OXADIAZOL-2-YL][3-[4-	0.026–0.047	2
(3-(4-(2-OXA-6-AZASPIRO[3.3]HEPTAN-6-YLMETHYL)PH	0.542	1
(5Z,11Z,14Z)-8,9-EPOXYEICOSATRIENOIC ACID	0.001	1
(5Z,8Z,11Z)-14,15-EPOXYEICOSATRIENOIC ACID	0.0003	1
(5Z,8Z,14Z)-11,12-EPOXYEICOSATRIENOIC ACID	0.0005	1
(8Z,11Z,14Z)-5,6-EPOXYEICOSATRIENOIC ACID	0.001	1

Catalyzed reactions (Rhea), 5 shown:

• cis-stilbene oxide + H2O = (1R,2R)-hydrobenzoin (RHEA:23900)
• 2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-glycerol + H2O = glycerol + (5Z,8Z,11Z,14Z)-eicosatetraenoate + H(+) (RHEA:26132)
• 11,12-epoxy-(5Z,8Z,14Z)-eicosatrienoate + H2O = 11,12-dihydroxy-(5Z,8Z,14Z)-eicosatrienoate (RHEA:44044)
• 8,9-epoxy-(5Z,11Z,14Z)-eicosatrienoate + H2O = 8,9-dihydroxy-(5Z,11Z,14Z)-eicosatrienoate (RHEA:44048)
• 1-(4-methoxyphenyl)-N-methyl-N-[(3-methyloxetan-3-yl)methyl]methanamine + H2O = 2-{[(4-methoxybenzyl)(methyl)amino]methyl}-2-methylpropane-1,3-diol (RHEA:55764)

UniProt features (26 total): sequence variant 12, sequence conflict 7, active site 3, chain 1, transmembrane region 1, topological domain 1, modified residue 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P07099-F1	95.06	0.86

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (3): 226 (nucleophile); 374 (proton donor); 431 (proton acceptor)

Post-translational modifications (1): 295

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-211945	Phase I - Functionalization of compounds

MSigDB gene sets: 329 (showing top): KOBAYASHI_EGFR_SIGNALING_24HR_UP, REACTOME_BIOLOGICAL_OXIDATIONS, CHIARADONNA_NEOPLASTIC_TRANSFORMATION_KRAS_DN, BECKER_TAMOXIFEN_RESISTANCE_UP, GOZGIT_ESR1_TARGETS_DN, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_UP, DACOSTA_UV_RESPONSE_VIA_ERCC3_UP, GOBP_LONG_CHAIN_FATTY_ACID_METABOLIC_PROCESS, GOBP_MONOCARBOXYLIC_ACID_METABOLIC_PROCESS, MODULE_66, WANG_ESOPHAGUS_CANCER_VS_NORMAL_DN, MARTINEZ_RB1_TARGETS_UP, PICCALUGA_ANGIOIMMUNOBLASTIC_LYMPHOMA_UP, MODULE_75

GO Biological Process (6): xenobiotic metabolic process (GO:0006805), response to toxic substance (GO:0009636), arachidonate metabolic process (GO:0019369), epoxide metabolic process (GO:0097176), hydrocarbon catabolic process (GO:0120253), lipid metabolic process (GO:0006629)

GO Molecular Function (7): epoxide hydrolase activity (GO:0004301), oxysterol binding (GO:0008142), cis-stilbene-oxide hydrolase activity (GO:0033961), catalytic activity (GO:0003824), protein binding (GO:0005515), hydrolase activity (GO:0016787), ether hydrolase activity (GO:0016803)

GO Cellular Component (3): endoplasmic reticulum membrane (GO:0005789), endoplasmic reticulum (GO:0005783), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Biological oxidations	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
metabolic process	2
cellular response to xenobiotic stimulus	1
response to chemical	1
long-chain fatty acid metabolic process	1
icosanoid metabolic process	1
unsaturated fatty acid metabolic process	1
olefinic compound metabolic process	1
catabolic process	1
hydrocarbon metabolic process	1
primary metabolic process	1
ether hydrolase activity	1
sterol binding	1
epoxide hydrolase activity	1
molecular_function	1
binding	1
catalytic activity	1
hydrolase activity, acting on ether bonds	1
organelle membrane	1
nuclear outer membrane-endoplasmic reticulum membrane network	1
endoplasmic reticulum subcompartment	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1
cellular anatomical structure	1

Protein interactions and networks

STRING

2442 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
EPHX1	GSTP1	P09211	894
EPHX1	CYP1A1	P04798	853
EPHX1	GSTM1	P09488	849
EPHX1	GGCX	P38435	824
EPHX1	NQO1	P15559	767
EPHX1	VKORC1	Q9BQB6	766
EPHX1	CYP2E1	P05181	700
EPHX1	EPHX2	P34913	690
EPHX1	SLC10A1	Q14973	667
EPHX1	EPHX3	Q9H6B9	666
EPHX1	GSTA1	P08263	661
EPHX1	CYP1B1	Q16678	652
EPHX1	BAAT	Q14032	631
EPHX1	CYP2C9	P11712	630
EPHX1	UGT1A8	Q9HAW9	629

IntAct

84 interactions, top by confidence:

A	B	Type	Score
ENTREP1	WWP2	psi-mi:“MI:0914”(association)	0.850
ESYT1	ESYT2	psi-mi:“MI:0914”(association)	0.770
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
EPHX1	MFSD8	psi-mi:“MI:0914”(association)	0.640
EPHX1	BDNF	psi-mi:“MI:0915”(physical association)	0.560
SPINT2	UPK3BL1	psi-mi:“MI:0914”(association)	0.530
EVA1C	UPK3BL1	psi-mi:“MI:0914”(association)	0.530
KCNS3	UPK3BL1	psi-mi:“MI:0914”(association)	0.530
TSPAN17	UPK3BL1	psi-mi:“MI:0914”(association)	0.530
PTGER3	PIK3R2	psi-mi:“MI:0914”(association)	0.530
SRPRB	CTDNEP1	psi-mi:“MI:0914”(association)	0.530
WASHC3	WASH3P	psi-mi:“MI:0914”(association)	0.530
SIDT2	AP3D1	psi-mi:“MI:0914”(association)	0.530
SLC6A8	ILVBL	psi-mi:“MI:0914”(association)	0.530
EPHX1	CFTR	psi-mi:“MI:0915”(physical association)	0.520
CFTR	EPHX1	psi-mi:“MI:0915”(physical association)	0.520
sseJ	AGPS	psi-mi:“MI:0914”(association)	0.460
IFT20	EPHX1	psi-mi:“MI:0915”(physical association)	0.400
PCDHGB4	FAM171A2	psi-mi:“MI:0914”(association)	0.350
TMEM30A	UPK3BL1	psi-mi:“MI:0914”(association)	0.350
SRPRB	GOSR1	psi-mi:“MI:0914”(association)	0.350
PCDHGA5	MAP2K7	psi-mi:“MI:0914”(association)	0.350

BioGRID (152): EPHX1 (Affinity Capture-RNA), EPHX1 (Affinity Capture-MS), EPHX1 (Affinity Capture-MS), EPHX1 (Affinity Capture-MS), EPHX1 (Affinity Capture-MS), EPHX1 (Affinity Capture-MS), EPHX1 (Affinity Capture-MS), EPHX1 (Affinity Capture-MS), EPHX1 (Affinity Capture-MS), EPHX1 (Affinity Capture-MS), EPHX1 (Affinity Capture-MS), EPHX1 (Affinity Capture-MS), EPHX1 (Affinity Capture-MS), EPHX1 (Co-fractionation), EPHX1 (Co-fractionation)

ESM2 similar proteins: A5D6U8, A6H730, J3SDX8, O16956, O35409, O61866, O75795, P04068, P04634, P07098, P07099, P07687, P08430, P0DTE5, P11515, P19224, P21529, P36510, P37891, P38571, P49614, P70627, P70691, P79381, P80035, Q28611, Q29458, Q38924, Q3U4B4, Q3YBN2, Q41005, Q4R4S5, Q5VXI9, Q5VXJ0, Q5VYY2, Q5W064, Q64194, Q64435, Q64550, Q67ZU1

Diamond homologs: A0A0E4AE82, A0A1L5BTC1, A5I3F5, A8YWL3, B0SY51, B1ZB18, B2HJU9, B4RF90, B8H3S9, B9JLT6, D4Z2G1, D5H0J3, I6YC03, O06734, O31168, O31581, O33472, O34592, O52866, P04068, P07099, P07383, P0A3G2, P0A3G3, P0A3G4, P0DO70, P19076, P27747, P29715, P46542, P46544, P52278, P53750, P59336, P64302, P64304, P66778, P95276, P9WGS2, P9WGS3

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

145 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	1
Uncertain significance	70
Likely benign	6
Benign	45

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
3247986	NC_000001.10:g.(?225591005)(227174438_?)del	Pathogenic
3376999	NM_001136018.4(EPHX1):c.251G>A (p.Gly84Asp)	Likely pathogenic

SpliceAI

1914 predictions. Top by Δscore:

Variant	Effect	Δscore
1:225810166:GACC:G	donor_gain	1.0000
1:225810170:G:GG	donor_gain	1.0000
1:225828723:A:AG	acceptor_gain	1.0000
1:225828724:G:GG	acceptor_gain	1.0000
1:225828899:A:G	donor_gain	1.0000
1:225828913:G:GG	donor_gain	1.0000
1:225838650:CCA:C	acceptor_loss	1.0000
1:225838651:CAGGG:C	acceptor_loss	1.0000
1:225838652:A:AC	acceptor_loss	1.0000
1:225838652:A:AG	acceptor_gain	1.0000
1:225838652:AG:A	acceptor_gain	1.0000
1:225838653:G:GG	acceptor_gain	1.0000
1:225838653:G:GT	acceptor_loss	1.0000
1:225838653:GG:G	acceptor_gain	1.0000
1:225838653:GGGCT:G	acceptor_gain	1.0000
1:225838801:GCC:G	donor_gain	1.0000
1:225838824:G:GT	donor_gain	1.0000
1:225838877:GAAGG:G	donor_gain	1.0000
1:225838880:GG:G	donor_gain	1.0000
1:225838881:GG:G	donor_gain	1.0000
1:225839209:A:AG	acceptor_gain	1.0000
1:225839209:ACT:A	acceptor_gain	1.0000
1:225839215:AG:A	acceptor_gain	1.0000
1:225839216:GG:G	acceptor_gain	1.0000
1:225839295:G:GT	donor_gain	1.0000
1:225839340:TGCCC:T	donor_gain	1.0000
1:225839344:CAG:C	donor_loss	1.0000
1:225839345:AGG:A	donor_loss	1.0000
1:225839347:GT:G	donor_loss	1.0000
1:225839348:T:G	donor_loss	1.0000

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000055447 (1:225843180 C>CA), RS1000109880 (1:225835361 G>A,C), RS1000194442 (1:225809628 A>G), RS1000300319 (1:225818336 C>T), RS1000351045 (1:225818510 G>T), RS1000456553 (1:225841370 C>T), RS1000631084 (1:225817981 G>A,T), RS1000747759 (1:225825676 T>G), RS1000908690 (1:225823818 G>A), RS1000920845 (1:225816627 C>G,T), RS1000954186 (1:225812621 G>A), RS1001026367 (1:225812843 A>G), RS1001038471 (1:225828872 T>C), RS1001039974 (1:225819969 T>C), RS1001188526 (1:225818905 A>G)

Disease associations

OMIM: gene MIM:132810 | disease phenotypes: MIM:219700, MIM:607748

GenCC curated gene-disease

Disease	Classification	Inheritance
hereditary lipodystrophy	Strong	Autosomal dominant
familial hypercholanemia	Supportive	Autosomal recessive
hereditary nonpolyposis colon cancer	Limited	Unknown

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
hereditary nonpolyposis colon cancer	Limited	AD

Mondo (7): cystic fibrosis (MONDO:0009061), hypercholanemia, familial 1 (MONDO:0031446), neutropenia (MONDO:0001475), lymphopenia (MONDO:0003783), hereditary lipodystrophy (MONDO:0020087), hereditary nonpolyposis colon cancer (MONDO:0018630), (MONDO:0011905)

Orphanet (3): Cystic fibrosis (Orphanet:586), Familial hypercholanemia (Orphanet:238475), Genetic lipodystrophy (Orphanet:98305)

HPO phenotypes

2 total (2 of 2 shown, HPO-id order):

HPO	Term
HP:0001875	Decreased total neutrophil count
HP:0001888	Decreased total lymphocyte count

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST003445_13	Response to cyclophosphamide in systemic lupus erythematosus with lupus nephritis	7.000000e-06
GCST010105_55	Nicotine dependence symptom count	2.000000e-06

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0009262	nicotine dependence symptom count

MeSH disease descriptors (4)

Descriptor	Name	Tree numbers
D003550	Cystic Fibrosis	C06.689.202; C08.381.187; C16.320.190; C16.614.213
D008231	Lymphopenia	C15.378.243.750.605; C15.378.553.546.605; C20.673.627
D009503	Neutropenia	C15.378.243.750.184.564; C15.378.553.546.184.564
C564336	Hypercholanemia, Familial (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (2): CHEMBL1968 (SINGLE PROTEIN), CHEMBL4523609 (PROTEIN FAMILY)

Molecules with ChEMBL bioactivity

2 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 15,759 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1076347	TRICLOCARBAN	2	15,622
CHEMBL436774	AR9281	2	137

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

10 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs1051740	Toxicity	3	phenytoin	Congenital Abnormalities;Disorder of facial skeleton
rs1051740	Toxicity	3	cisplatin;cyclophosphamide	Ovarian Neoplasms
rs1051740	Efficacy	3	phenprocoumon
rs1051740	Metabolism/PK	3	carbamazepine	Epilepsy
rs1051740	Dosage	3	carbamazepine	Epilepsy
rs1131873	Dosage	4	warfarin
rs1877724	Dosage	3	warfarin
rs2234922	Toxicity	3	phenytoin	Congenital Abnormalities;Disorder of facial skeleton
rs2234922	Dosage	3	docetaxel	Non-Small Cell Lung Carcinoma
rs2234922	Dosage	3	carbamazepine	Epilepsy

PharmGKB variants

8 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs1051740	EPHX1	3	5.75	5	phenytoin;carbamazepine;cisplatin;cyclophosphamide;phenprocoumon
rs1051741	EPHX1, TMEM63A		0.00	0
rs1131873	EPHX1	4	-0.75	1	warfarin
rs1877724	EPHX1	3	2.25	1	warfarin
rs2234922	EPHX1	3	4.25	3	phenytoin;docetaxel;carbamazepine
rs2260863	EPHX1		0.00	0
rs3738046	EPHX1		0.00	0
rs4653436	EPHX1		0.00	0

Binding affinities (BindingDB)

244 measured of 244 human assays (256 total across all organisms); most potent 50 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
1-[4-(trifluoromethoxy)phenyl]-3-[1-[4-(trifluoromethyl)phenyl]sulfonylpiperidin-4-yl]urea	IC50	0.4 nM	US-8501783: Conformationally restricted urea inhibitors of soluble epoxide hydrolase
1-(1-(Trifluoroacetyl)piperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea	IC50	0.4 nM	US-9296693: Acyl piperidine inhibitors of soluble epoxide hydrolase
1-(1-Tosylpiperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea	IC50	0.4 nM	US-9296693: Acyl piperidine inhibitors of soluble epoxide hydrolase
4-[4-[(12-chloro-10-tetracyclo[8.3.1.18,12.02,7]pentadeca-2,4,6-trienyl)carbamoylamino]cyclohexyl]oxybenzoic acid	IC50	0.4 nM	US-20240182406: COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS
1-(12-methyl-10-tetracyclo[8.3.1.18,12.02,7]pentadeca-2,4,6-trienyl)-3-(1-propan-2-ylsulfonylpiperidin-4-yl)urea	IC50	0.4 nM	US-20240182406: COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS
1-[1-(cyclopropanecarbonyl)piperidin-4-yl]-3-(12-methyl-10-tetracyclo[8.3.1.18,12.02,7]pentadeca-2,4,6-trienyl)urea	IC50	0.4 nM	US-20240182406: COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS
1-(12-chloro-10-tetracyclo[8.3.1.18,12.02,7]pentadeca-2,4,6-trienyl)-3-[1-(oxane-4-carbonyl)piperidin-4-yl]urea	IC50	0.4 nM	US-20240182406: COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS
1-(12-chloro-10-tetracyclo[8.3.1.18,12.02,7]pentadeca-2,4,6-trienyl)-3-[1-(cyclopropanecarbonyl)piperidin-4-yl]urea	IC50	0.4 nM	US-20240182406: COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS
1-(12-chloro-10-tetracyclo[8.3.1.18,12.02,7]pentadeca-2,4,6-trienyl)-3-[1-(2,2,2-trifluoroacetyl)piperidin-4-yl]urea	IC50	0.4 nM	US-20240182406: COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS
1-(12-fluoro-10-tetracyclo[8.3.1.18,12.02,7]pentadeca-2,4,6-trienyl)-3-[1-(oxane-4-carbonyl)piperidin-4-yl]urea	IC50	0.4 nM	US-20240182406: COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS
1-[1-(cyclopropanecarbonyl)piperidin-4-yl]-3-(12-fluoro-10-tetracyclo[8.3.1.18,12.02,7]pentadeca-2,4,6-trienyl)urea	IC50	0.4 nM	US-20240182406: COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS
1-(9-chloro-2,3-dimethoxy-5,6,8,9,10,11-hexahydro-7H-5,9:7,11-dimethanobenzo[9]annulen-7-yl)-3-(1-(tetrahydro-2H-pyran-4-carbonyl)piperidin-4-yl)urea	IC50	0.4 nM	US-20240182406: COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS
4-(4-(3-(9-chloro-5,6,8,9,10,11-hexahydro-7H-5,9:7,11-dimethanobenzo[9]annulen-7-yl)ureido)piperidin-1-yl)benzoic acid	IC50	0.4 nM	US-20240182406: COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS
4-(4-(3-(9-chloro-5,6,8,9,10,11-hexahydro-7H-5,9:7,11-dimethanobenzo[9]annulen-7-yl)ureido)piperidine-1-carbonyl)benzoic acid	IC50	0.4 nM	US-20240182406: COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS
4-[4-[(12-fluoro-10-tetracyclo[8.3.1.18,12.02,7]pentadeca-2,4,6-trienyl)carbamoylamino]cyclohexyl]oxybenzoic acid	IC50	0.5 nM	US-20240182406: COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS
4-(4-(3-(9-fluoro-5,6,8,9,10,11-hexahydro-7H-5,9:7,11-dimethanobenzo[9]annulen-7-yl)ureido)piperidin-1-yl)benzoic acid	IC50	0.5 nM	US-20240182406: COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS
1-(12-chloro-10-tetracyclo[8.3.1.18,12.02,7]pentadeca-2,4,6-trienyl)-3-(1-propanoylpiperidin-4-yl)urea	IC50	0.6 nM	US-20240182406: COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS
1-(12-chloro-10-tetracyclo[8.3.1.18,12.02,7]pentadeca-2,4,6-trienyl)-3-(1-propan-2-ylsulfonylpiperidin-4-yl)urea	IC50	0.6 nM	US-20240182406: COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS
1-(12-chloro-10-tetracyclo[8.3.1.18,12.02,7]pentadeca-2,4,6-trienyl)-3-[1-(1-fluorocyclopropanecarbonyl)piperidin-4-yl]urea	IC50	0.6 nM	US-20240182406: COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS
1-(9-fluoro-2,3-dimethoxy-5,6,8,9,10,11-hexahydro-7H-5,9:7,11-dimethanobenzo[9]annulen-7-yl)-3-(1-(tetrahydro-2H-pyran-4-carbonyl)piperidin-4-yl)urea	IC50	0.6 nM	US-20240182406: COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS
1-(1-(5-(Dimethylamino)naphthalen-1-ylsulfonyl)piperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea	IC50	0.8 nM	US-9296693: Acyl piperidine inhibitors of soluble epoxide hydrolase
methyl 4-(1-adamantylcarbamoylamino)piperidine-1-carboxylate	IC50	0.9 nM	US-8501783: Conformationally restricted urea inhibitors of soluble epoxide hydrolase
1-(1-acetylpiperidin-4-yl)-3-(2-fluoro-9-methyl-5,6,8,9,10,11-hexahydro-7H-5,9:7,11-dimethanobenzo[9]annulen-7-yl)urea	IC50	0.9 nM	US-20240182406: COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS
1-(1-acetylpiperidin-4-yl)-3-(1-fluoro-9-methyl-5,6,8,9,10,11-hexahydro-7H-5,9:7,11-dimethanobenzo[9]annulen-7-yl)urea	IC50	0.9 nM	US-20240182406: COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS
1-(12-methyl-10-tetracyclo[8.3.1.18,12.02,7]pentadeca-2,4,6-trienyl)-3-[1-(oxane-4-carbonyl)piperidin-4-yl]urea	IC50	1 nM	US-20240182406: COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS
1-(1-adamantyl)-3-[1-(2,2,2-trifluoroacetyl)piperidin-4-yl]urea	IC50	1.1 nM	US-8501783: Conformationally restricted urea inhibitors of soluble epoxide hydrolase
methyl 4-[4-(1-adamantylcarbamoylamino)piperidine-1-carbonyl]benzoate	IC50	1.1 nM	US-8501783: Conformationally restricted urea inhibitors of soluble epoxide hydrolase
methyl 3-[4-[(1-adamantylcarbamoylamino)methyl]piperidine-1-carbonyl]benzoate	IC50	1.1 nM	US-8501783: Conformationally restricted urea inhibitors of soluble epoxide hydrolase
methyl 4-[4-[(1-adamantylcarbamoylamino)methyl]piperidine-1-carbonyl]benzoate	IC50	1.1 nM	US-8501783: Conformationally restricted urea inhibitors of soluble epoxide hydrolase
1-(12-methyl-10-tetracyclo[8.3.1.18,12.02,7]pentadeca-2,4,6-trienyl)-3-(2,3,4-trifluorophenyl)urea	IC50	1.1 nM	US-20240182406: COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS
1-(12-methyl-10-tetracyclo[8.3.1.18,12.02,7]pentadeca-2,4,6-trienyl)-3-(1-propanoylpiperidin-4-yl)urea	IC50	1.1 nM	US-20240182406: COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS
1-(1-adamantyl)-3-[1-(pyridine-2-carbonyl)piperidin-4-yl]urea	IC50	1.2 nM	US-8501783: Conformationally restricted urea inhibitors of soluble epoxide hydrolase
1-(1-acetylpiperidin-4-yl)-3-(2-methoxy-9-methyl-5,6,8,9,10,11-hexahydro-7H-5,9:7,11-dimethanobenzo[9]annulen-7-yl)urea	IC50	1.2 nM	US-20240182406: COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS
1-(1-adamantyl)-3-(1-benzoylpiperidin-4-yl)urea	IC50	1.3 nM	US-8501783: Conformationally restricted urea inhibitors of soluble epoxide hydrolase
1-(1-adamantyl)-3-(1-methylsulfonylpiperidin-4-yl)urea	IC50	1.4 nM	US-8501783: Conformationally restricted urea inhibitors of soluble epoxide hydrolase
1-(1-benzylpiperidin-4-yl)-3-(9-methyl-5,6,8,9,10,11-hexahydro-7H-5,9:7,11-dimethanobenzo[9]annulen-7-yl)urea	IC50	1.5 nM	US-20240182406: COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS
1-(1-adamantyl)-3-[1-(pyridine-4-carbonyl)piperidin-4-yl]urea	IC50	1.7 nM	US-8501783: Conformationally restricted urea inhibitors of soluble epoxide hydrolase
methyl 2-[4-(1-adamantylcarbamoylamino)piperidine-1-carbonyl]benzoate	IC50	1.7 nM	US-8501783: Conformationally restricted urea inhibitors of soluble epoxide hydrolase
1-(1-adamantyl)-3-[1-(2,2,2-trifluoroacetyl)piperidin-4-yl]urea	IC50	1.7 nM	US-8501783: Conformationally restricted urea inhibitors of soluble epoxide hydrolase
methyl 2-[4-[(1-adamantylcarbamoylamino)methyl]piperidine-1-carbonyl]benzoate	IC50	1.8 nM	US-8501783: Conformationally restricted urea inhibitors of soluble epoxide hydrolase
1-(1-adamantyl)-3-[[1-(2,2,2-trifluoroacetyl)piperidin-4-yl]methyl]urea	IC50	1.8 nM	US-8501783: Conformationally restricted urea inhibitors of soluble epoxide hydrolase
1-(1-adamantyl)-3-[1-(pyridine-3-carbonyl)piperidin-4-yl]urea	IC50	2.1 nM	US-8501783: Conformationally restricted urea inhibitors of soluble epoxide hydrolase
1-(1-adamantyl)-3-(1-butanoylpiperidin-4-yl)urea	IC50	2.64 nM	US-8501783: Conformationally restricted urea inhibitors of soluble epoxide hydrolase
methyl 5-[4-(1-adamantylcarbamoylamino)piperidin-1-yl]-5-oxopentanoate	IC50	2.7 nM	US-8501783: Conformationally restricted urea inhibitors of soluble epoxide hydrolase
1-(1-(4-acetylphenyl)piperidin-4-yl)-3-(9-methyl-5,6,8,9,10,11-hexahydro-7H-5,9:7,11-dimethanobenzo[9]annulen-7-yl)urea	IC50	2.9 nM	US-20240182406: COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS
1-(1-adamantyl)-3-(1-propanoylpiperidin-4-yl)urea	IC50	3.19 nM	US-8501783: Conformationally restricted urea inhibitors of soluble epoxide hydrolase
1-(1-adamantyl)-3-(1-propanoylpiperidin-4-yl)urea	IC50	3.2 nM	US-8501783: Conformationally restricted urea inhibitors of soluble epoxide hydrolase
1-(1-adamantyl)-3-[(1-benzoylpiperidin-4-yl)methyl]urea	IC50	3.2 nM	US-8501783: Conformationally restricted urea inhibitors of soluble epoxide hydrolase
4-[4-(1-adamantylcarbamoylamino)piperidine-1-carbonyl]benzoic acid	IC50	3.3 nM	US-8501783: Conformationally restricted urea inhibitors of soluble epoxide hydrolase
methyl 5-[4-[(1-adamantylcarbamoylamino)methyl]piperidin-1-yl]-5-oxopentanoate	IC50	3.4 nM	US-8501783: Conformationally restricted urea inhibitors of soluble epoxide hydrolase

ChEMBL bioactivities

314 potent at pChembl≥5 of 365 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
9.40	IC50	0.4	nM	CHEMBL1257517
9.40	IC50	0.4	nM	CHEMBL1257759
9.40	IC50	0.4	nM	CHEMBL3642246
9.10	IC50	0.8	nM	CHEMBL1257880
9.05	IC50	0.9	nM	CHEMBL3642245
9.03	IC50	0.94	nM	CHEMBL4741234
8.96	IC50	1.1	nM	CHEMBL215121
8.96	IC50	1.1	nM	CHEMBL215908
8.96	IC50	1.1	nM	CHEMBL217758
8.96	IC50	1.1	nM	CHEMBL215999
8.92	IC50	1.2	nM	CHEMBL215161
8.89	IC50	1.3	nM	CHEMBL216016
8.85	IC50	1.4	nM	CHEMBL1668935
8.82	IC50	1.5	nM	CHEMBL215908
8.77	IC50	1.7	nM	CHEMBL214179
8.77	IC50	1.7	nM	CHEMBL214644
8.77	IC50	1.7	nM	CHEMBL217758
8.74	IC50	1.8	nM	CHEMBL384280
8.74	IC50	1.8	nM	CHEMBL214127
8.68	IC50	2.1	nM	CHEMBL214128
8.66	IC50	2.2	nM	CHEMBL4741234
8.58	IC50	2.64	nM	CHEMBL215125
8.57	IC50	2.7	nM	CHEMBL214505
8.50	IC50	3.19	nM	CHEMBL214943
8.49	IC50	3.2	nM	CHEMBL214943
8.49	IC50	3.2	nM	CHEMBL214883
8.48	IC50	3.3	nM	CHEMBL386384
8.47	IC50	3.4	nM	CHEMBL384075
8.39	IC50	4.1	nM	CHEMBL215121
8.37	IC50	4.3	nM	CHEMBL3640214
8.33	IC50	4.7	nM	CHEMBL4761537
8.32	IC50	4.8	nM	CHEMBL3642240
8.30	IC50	5	nM	CHEMBL215025
8.27	IC50	5.4	nM	CHEMBL215069
8.21	IC50	6.2	nM	CHEMBL217711
8.17	IC50	6.7	nM	CHEMBL214675
8.14	IC50	7.3	nM	CHEMBL425436
8.12	IC50	7.6	nM	CHEMBL386855
8.08	IC50	8.4	nM	CHEMBL387034
8.06	IC50	8.7	nM	CHEMBL215874
8.05	IC50	9	nM	CHEMBL215827
8.05	IC50	9	nM	CHEMBL4759724
8.00	IC50	10.1	nM	CHEMBL385946
8.00	IC50	10.1	nM	CHEMBL4744212
8.00	IC50	10	nM	CHEMBL4778376
8.00	IC50	10	nM	CHEMBL387034
7.96	IC50	11	nM	CHEMBL4785066
7.94	IC50	11.5	nM	CHEMBL1668934
7.93	IC50	11.8	nM	CHEMBL387280
7.85	IC50	14	nM	CHEMBL4758328

PubChem BioAssay actives

64 with measured affinity, of 392 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
2-[[3,5-bis(trifluoromethyl)phenyl]methylsulfanyl]-2-cyclopentylacetamide	1691500: Inhibition of tissue extract derived mEH (unknown origin) using [3H]trans-stilbene oxide as substrate by liquid scintillation counting method	ic50	0.0009	uM
2-cyclopentyl-2-[1-[3-(trifluoromethyl)phenyl]ethylsulfanyl]acetamide	1691497: Inhibition of human mEH using CMNGC as substrate preincubated for 5 mins followed by substrate addition and measured at 30 secs interval for 10 mins by fluorescence assay	ic50	0.0047	uM
2-cyclopentyl-2-[(3,5-dibromophenyl)methylsulfanyl]acetamide	1691497: Inhibition of human mEH using CMNGC as substrate preincubated for 5 mins followed by substrate addition and measured at 30 secs interval for 10 mins by fluorescence assay	ic50	0.0090	uM
2-[[4-chloro-3-(trifluoromethoxy)phenyl]methylsulfanyl]-2-cyclopentylacetamide	1691497: Inhibition of human mEH using CMNGC as substrate preincubated for 5 mins followed by substrate addition and measured at 30 secs interval for 10 mins by fluorescence assay	ic50	0.0100	uM
2-cyclopentyl-2-[[4-fluoro-3-(trifluoromethyl)phenyl]methylsulfanyl]acetamide	1691497: Inhibition of human mEH using CMNGC as substrate preincubated for 5 mins followed by substrate addition and measured at 30 secs interval for 10 mins by fluorescence assay	ic50	0.0101	uM
2-cyclopentyl-2-[(3,5-dichlorophenyl)methylsulfanyl]acetamide	1691497: Inhibition of human mEH using CMNGC as substrate preincubated for 5 mins followed by substrate addition and measured at 30 secs interval for 10 mins by fluorescence assay	ic50	0.0110	uM
2-cyclopentyl-2-[2-[3-(trifluoromethyl)phenyl]ethylsulfanyl]acetamide	1691497: Inhibition of human mEH using CMNGC as substrate preincubated for 5 mins followed by substrate addition and measured at 30 secs interval for 10 mins by fluorescence assay	ic50	0.0140	uM
2-cyclopentyl-2-[[3-(trifluoromethyl)phenyl]methylsulfanyl]acetamide	1691497: Inhibition of human mEH using CMNGC as substrate preincubated for 5 mins followed by substrate addition and measured at 30 secs interval for 10 mins by fluorescence assay	ic50	0.0160	uM
2-cyclopentyl-2-[(3,5-dimethylphenyl)methylsulfanyl]acetamide	1691497: Inhibition of human mEH using CMNGC as substrate preincubated for 5 mins followed by substrate addition and measured at 30 secs interval for 10 mins by fluorescence assay	ic50	0.0180	uM
2-cyclohexyl-2-[[3-(trifluoromethyl)phenyl]methylsulfanyl]acetamide	1691497: Inhibition of human mEH using CMNGC as substrate preincubated for 5 mins followed by substrate addition and measured at 30 secs interval for 10 mins by fluorescence assay	ic50	0.0190	uM
2,2-bis[[3-(trifluoromethyl)phenyl]methylsulfanyl]acetamide	1691497: Inhibition of human mEH using CMNGC as substrate preincubated for 5 mins followed by substrate addition and measured at 30 secs interval for 10 mins by fluorescence assay	ic50	0.0230	uM
2-cyclopentyl-2-[[3-(trifluoromethoxy)phenyl]methylsulfanyl]acetamide	1691497: Inhibition of human mEH using CMNGC as substrate preincubated for 5 mins followed by substrate addition and measured at 30 secs interval for 10 mins by fluorescence assay	ic50	0.0260	uM
4-methyl-2-[[3-(trifluoromethyl)phenyl]methylsulfanyl]pentanamide	1691497: Inhibition of human mEH using CMNGC as substrate preincubated for 5 mins followed by substrate addition and measured at 30 secs interval for 10 mins by fluorescence assay	ic50	0.0280	uM
2-[[3-(trifluoromethyl)phenyl]methylsulfanyl]hexanamide	1691497: Inhibition of human mEH using CMNGC as substrate preincubated for 5 mins followed by substrate addition and measured at 30 secs interval for 10 mins by fluorescence assay	ic50	0.0290	uM
2-cyclopentyl-2-[(3-nitrophenyl)methylsulfanyl]acetamide	1691497: Inhibition of human mEH using CMNGC as substrate preincubated for 5 mins followed by substrate addition and measured at 30 secs interval for 10 mins by fluorescence assay	ic50	0.0320	uM
2-cyclopentyl-2-(naphthalen-2-ylmethylsulfanyl)acetamide	1691497: Inhibition of human mEH using CMNGC as substrate preincubated for 5 mins followed by substrate addition and measured at 30 secs interval for 10 mins by fluorescence assay	ic50	0.0330	uM
3-methyl-2-[[3-(trifluoromethyl)phenyl]methylsulfanyl]butanamide	1691497: Inhibition of human mEH using CMNGC as substrate preincubated for 5 mins followed by substrate addition and measured at 30 secs interval for 10 mins by fluorescence assay	ic50	0.0880	uM
2-[(4-bromophenyl)methylsulfanyl]-3-methylbutanamide	1691497: Inhibition of human mEH using CMNGC as substrate preincubated for 5 mins followed by substrate addition and measured at 30 secs interval for 10 mins by fluorescence assay	ic50	0.1000	uM
2-[(4-bromophenyl)methylsulfanyl]-2-phenylacetamide	1691497: Inhibition of human mEH using CMNGC as substrate preincubated for 5 mins followed by substrate addition and measured at 30 secs interval for 10 mins by fluorescence assay	ic50	0.1100	uM
2-phenyl-2-[[3-(trifluoromethyl)phenyl]methylsulfanyl]acetamide	1691497: Inhibition of human mEH using CMNGC as substrate preincubated for 5 mins followed by substrate addition and measured at 30 secs interval for 10 mins by fluorescence assay	ic50	0.1400	uM
2-[(2,4-dichlorophenyl)methylsulfanyl]-3-methylbutanamide	1691497: Inhibition of human mEH using CMNGC as substrate preincubated for 5 mins followed by substrate addition and measured at 30 secs interval for 10 mins by fluorescence assay	ic50	0.1400	uM
2-[[3-(trifluoromethyl)phenyl]methylsulfanyl]pentanamide	1691497: Inhibition of human mEH using CMNGC as substrate preincubated for 5 mins followed by substrate addition and measured at 30 secs interval for 10 mins by fluorescence assay	ic50	0.1500	uM
2-[(3-cyanophenyl)methylsulfanyl]-2-cyclopentylacetamide	1691497: Inhibition of human mEH using CMNGC as substrate preincubated for 5 mins followed by substrate addition and measured at 30 secs interval for 10 mins by fluorescence assay	ic50	0.1930	uM
2-[(2,4-dichlorophenyl)methylsulfanyl]-2-phenylacetamide	1691497: Inhibition of human mEH using CMNGC as substrate preincubated for 5 mins followed by substrate addition and measured at 30 secs interval for 10 mins by fluorescence assay	ic50	0.2800	uM
2-cyclopentyl-2-[(4-nitrophenyl)methylsulfanyl]acetamide	1691497: Inhibition of human mEH using CMNGC as substrate preincubated for 5 mins followed by substrate addition and measured at 30 secs interval for 10 mins by fluorescence assay	ic50	0.3150	uM
2-[(3-acetylphenyl)methylsulfanyl]-2-cyclopentylacetamide	1691497: Inhibition of human mEH using CMNGC as substrate preincubated for 5 mins followed by substrate addition and measured at 30 secs interval for 10 mins by fluorescence assay	ic50	0.3840	uM
2-cyclopentyl-2-[(3,5-difluorophenyl)methylsulfanyl]acetamide	1691497: Inhibition of human mEH using CMNGC as substrate preincubated for 5 mins followed by substrate addition and measured at 30 secs interval for 10 mins by fluorescence assay	ic50	0.3990	uM
4-[(2-amino-1-cyclopentyl-2-oxoethyl)sulfanylmethyl]-N-[[2-(trifluoromethyl)phenyl]methyl]benzamide	1691497: Inhibition of human mEH using CMNGC as substrate preincubated for 5 mins followed by substrate addition and measured at 30 secs interval for 10 mins by fluorescence assay	ic50	0.4220	uM
2-[(4-tert-butylphenyl)methylsulfanyl]-3-methylbutanamide	1691497: Inhibition of human mEH using CMNGC as substrate preincubated for 5 mins followed by substrate addition and measured at 30 secs interval for 10 mins by fluorescence assay	ic50	0.4300	uM
3-[(2-amino-1-cyclopentyl-2-oxoethyl)sulfanylmethyl]-N-[[2-(trifluoromethyl)phenyl]methyl]benzamide	1691497: Inhibition of human mEH using CMNGC as substrate preincubated for 5 mins followed by substrate addition and measured at 30 secs interval for 10 mins by fluorescence assay	ic50	0.4330	uM
2-cyclopentyl-2-[(2,6-difluorophenyl)methylsulfanyl]acetamide	1691497: Inhibition of human mEH using CMNGC as substrate preincubated for 5 mins followed by substrate addition and measured at 30 secs interval for 10 mins by fluorescence assay	ic50	0.4410	uM
(2S)-2-[(4-tert-butylphenyl)methylsulfanyl]-2-phenylacetamide	1691497: Inhibition of human mEH using CMNGC as substrate preincubated for 5 mins followed by substrate addition and measured at 30 secs interval for 10 mins by fluorescence assay	ic50	0.4800	uM
2-[(2-chloro-4-pyridinyl)methylsulfanyl]-2-cyclopentylacetamide	1691497: Inhibition of human mEH using CMNGC as substrate preincubated for 5 mins followed by substrate addition and measured at 30 secs interval for 10 mins by fluorescence assay	ic50	0.4930	uM
tert-butyl 3-[(2-amino-1-cyclopentyl-2-oxoethyl)sulfanylmethyl]indole-1-carboxylate	1691497: Inhibition of human mEH using CMNGC as substrate preincubated for 5 mins followed by substrate addition and measured at 30 secs interval for 10 mins by fluorescence assay	ic50	0.5000	uM
2-phenyl-2-[[4-(trifluoromethoxy)phenyl]methylsulfanyl]acetamide	1691497: Inhibition of human mEH using CMNGC as substrate preincubated for 5 mins followed by substrate addition and measured at 30 secs interval for 10 mins by fluorescence assay	ic50	0.5000	uM
2-[(4-tert-butylphenyl)methylsulfanyl]-2-phenylacetamide	1691497: Inhibition of human mEH using CMNGC as substrate preincubated for 5 mins followed by substrate addition and measured at 30 secs interval for 10 mins by fluorescence assay	ic50	0.6400	uM
3-methyl-2-[[4-(trifluoromethoxy)phenyl]methylsulfanyl]butanamide	1691497: Inhibition of human mEH using CMNGC as substrate preincubated for 5 mins followed by substrate addition and measured at 30 secs interval for 10 mins by fluorescence assay	ic50	0.6700	uM
(2R)-2-[(4-tert-butylphenyl)methylsulfanyl]-2-phenylacetamide	1691497: Inhibition of human mEH using CMNGC as substrate preincubated for 5 mins followed by substrate addition and measured at 30 secs interval for 10 mins by fluorescence assay	ic50	0.6800	uM
2-(cyclohexylmethylsulfanyl)-2-cyclopentylacetamide	1691497: Inhibition of human mEH using CMNGC as substrate preincubated for 5 mins followed by substrate addition and measured at 30 secs interval for 10 mins by fluorescence assay	ic50	0.7730	uM
3-[(2-amino-1-cyclopentyl-2-oxoethyl)sulfanylmethyl]benzoic acid	1691497: Inhibition of human mEH using CMNGC as substrate preincubated for 5 mins followed by substrate addition and measured at 30 secs interval for 10 mins by fluorescence assay	ic50	0.8390	uM
2-[4-[(2-amino-1-cyclopentyl-2-oxoethyl)sulfanylmethyl]phenyl]propanoic acid	1691497: Inhibition of human mEH using CMNGC as substrate preincubated for 5 mins followed by substrate addition and measured at 30 secs interval for 10 mins by fluorescence assay	ic50	0.8990	uM
2-[(5-chloro-1-benzothiophen-3-yl)methylsulfanyl]-2-cyclopentylacetamide	1691497: Inhibition of human mEH using CMNGC as substrate preincubated for 5 mins followed by substrate addition and measured at 30 secs interval for 10 mins by fluorescence assay	ic50	1.1000	uM
2-[(6-chloro-3-pyridinyl)methylsulfanyl]-2-cyclopentylacetamide	1691497: Inhibition of human mEH using CMNGC as substrate preincubated for 5 mins followed by substrate addition and measured at 30 secs interval for 10 mins by fluorescence assay	ic50	1.4660	uM
2-nonylsulfanylpropanamide	1691497: Inhibition of human mEH using CMNGC as substrate preincubated for 5 mins followed by substrate addition and measured at 30 secs interval for 10 mins by fluorescence assay	ic50	1.5800	uM
2-[[3-(trifluoromethyl)phenyl]methylsulfanyl]propanamide	1691497: Inhibition of human mEH using CMNGC as substrate preincubated for 5 mins followed by substrate addition and measured at 30 secs interval for 10 mins by fluorescence assay	ic50	1.6000	uM
1,3-diphenylpropan-2-amine	1691497: Inhibition of human mEH using CMNGC as substrate preincubated for 5 mins followed by substrate addition and measured at 30 secs interval for 10 mins by fluorescence assay	ic50	1.9000	uM
2-[(4-fluorophenyl)methylsulfanyl]-2-phenylacetamide	1691497: Inhibition of human mEH using CMNGC as substrate preincubated for 5 mins followed by substrate addition and measured at 30 secs interval for 10 mins by fluorescence assay	ic50	2.0000	uM
2-[(4-cyanophenyl)methylsulfanyl]-2-cyclopentylacetamide	1691497: Inhibition of human mEH using CMNGC as substrate preincubated for 5 mins followed by substrate addition and measured at 30 secs interval for 10 mins by fluorescence assay	ic50	2.1000	uM
2,2-dicyclohexylethanamine	1691497: Inhibition of human mEH using CMNGC as substrate preincubated for 5 mins followed by substrate addition and measured at 30 secs interval for 10 mins by fluorescence assay	ic50	2.2000	uM
methyl 4-[(2-amino-1-cyclopentyl-2-oxoethyl)sulfanylmethyl]benzoate	1691497: Inhibition of human mEH using CMNGC as substrate preincubated for 5 mins followed by substrate addition and measured at 30 secs interval for 10 mins by fluorescence assay	ic50	2.9000	uM

CTD chemical–gene interactions

141 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects reaction, decreases expression, decreases methylation, increases expression, affects metabolic processing (+5 more)	9
bisphenol A	increases expression, affects response to substance, affects expression, affects cotreatment, increases methylation (+1 more)	8
Warfarin	affects response to substance, increases response to substance	7
Benzene	affects abundance, increases metabolic processing, increases expression, affects response to substance, affects metabolic processing	5
Phenobarbital	affects expression, increases expression	4
Polycyclic Aromatic Hydrocarbons	affects response to substance, decreases metabolic processing, increases metabolic processing	4
Tobacco Smoke Pollution	affects expression, decreases expression, increases expression	4
sodium arsenite	increases abundance, increases expression	3
1,3-butadiene	increases response to substance, increases reaction	3
glycidamide	affects abundance, affects cotreatment, affects metabolic processing, affects chemical synthesis, increases expression	3
Resveratrol	increases activity, increases reaction, increases expression	3
Air Pollutants	increases abundance, increases expression	3
Carbamazepine	increases expression, affects response to substance	3
Rifampin	decreases reaction, increases expression	3
Valproic Acid	affects expression, affects reaction, decreases expression, decreases methylation	3
Cyclosporine	affects cotreatment, decreases expression	3
bisphenol F	increases expression, affects cotreatment	2
styrene oxide	affects hydrolysis, affects metabolic processing, decreases activity	2
sulforaphane	affects binding, increases reaction, increases expression	2
cobaltous chloride	decreases expression, increases expression	2
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression, increases expression	2
(+)-JQ1 compound	increases expression	2
Asbestos	affects response to substance	2
Chenodeoxycholic Acid	affects cotreatment, decreases expression	2
Doxorubicin	increases expression	2
Estradiol	decreases expression, affects expression, affects cotreatment	2
Fluorouracil	affects response to substance, increases expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Silicon Dioxide	decreases expression, increases expression	2
Smoke	decreases expression, increases abundance, increases expression	2

ChEMBL screening assays

30 unique, capped per target: 18 binding, 12 admet

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1001507	Binding	Inhibition of human microsomal epoxide hydrolase	Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors. — Bioorg Med Chem Lett
CHEMBL4312960	ADMET	Drug metabolism in human liver microsomes assessed as mEH-mediated oxidoreductive ring-opening of azetidine by measuring [3-[4-[[[3-(hydroxymethyl)oxetan-3-yl]methylamino]methyl]phenoxy]azetidin-1-yl]-[5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-	Hip To Be Square: Oxetanes as Design Elements To Alter Metabolic Pathways. — J Med Chem

Cellosaurus cell lines

6 cell lines: 3 transformed cell line, 3 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_5332	MCL-5	Transformed cell line	Male
CVCL_D1MD	Abcam K-562 EPHX1 KO	Cancer cell line	Female
CVCL_D2IY	Abcam Raji EPHX1 KO	Cancer cell line	Male
CVCL_UQ45	Abcam Jurkat EPHX1 KO	Cancer cell line	Male
CVCL_UU63	MCL-1	Transformed cell line	Male
CVCL_UU64	MCL-2	Transformed cell line	Male

Clinical trials (associated diseases)

314 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00157690	PHASE4	COMPLETED	Study of Alendronate to Prevent and Treat Osteoporosis in Cystic Fibrosis Patients
NCT00208078	PHASE4	TERMINATED	Effect of Non-Invasive Ventilation in Cystic Fibrosis Patient With Chronic Respiratory Failure.
NCT00244270	PHASE4	COMPLETED	Cystic Fibrosis and Totally Implantable Vascular Access Devices
NCT00333385	PHASE4	TERMINATED	Continuous Versus Short Infusions of Ceftazidime in Cystic Fibrosis
NCT00411736	PHASE4	COMPLETED	Scandinavian Cystic Fibrosis Azithromycin Study
NCT00418470	PHASE4	TERMINATED	Prolonging the Duration of Peripheral Venous Catheters in Cystic Fibrosis People
NCT00431964	PHASE4	COMPLETED	Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa
NCT00434278	PHASE4	TERMINATED	A Trial of Pulmozyme Withdrawal on Exercise Tolerance in Cystic Fibrosis Subjects With Severe Lung Disease (TOPIC)
NCT00483769	PHASE4	COMPLETED	One Year Glargine Treatment in CFRD Children and Adolescents
NCT00528190	PHASE4	COMPLETED	Treatment of Aspergillus Fumigatus (a Fungal Infection) in Patients With Cystic Fibrosis
NCT00557089	PHASE4	COMPLETED	The Effect of rhDNase on Ventilation Inhomogeneity in Patients With Cystic Fibrosis
NCT00572975	PHASE4	COMPLETED	Malabsorption Blood Test:Toward a Novel Approach to Quantify Steatorrhea
NCT00680316	PHASE4	TERMINATED	A Study of Pulmozyme® (Dornase Alpha) in 3- to 5-Year-Old Patients With Cystic Fibrosis
NCT00685035	PHASE4	COMPLETED	Comparison of Airway Clearance Therapy in Cystic Fibrosis Using the Same VEST Therapy Device But With Different Settings
NCT00744250	PHASE4	TERMINATED	Intraduodenal Aspiration Study to Assess the Bioavailability of Oral Pancrecarb® Compared to Placebo Control
NCT00787917	PHASE4	TERMINATED	An Exploratory Study to Assess Multiple Doses of Omalizumab in Patients With Cystic Fibrosis Complicated by Acute Bronchopulmonary Aspergillosis (ABPA)
NCT00843817	PHASE4	COMPLETED	RhDNase and Biodistribution of PMN Serine Proteases in Cystic Fibrosis Sputum
NCT00890370	PHASE4	COMPLETED	Should Any One Airway Clearance Technique be Recommended for People With Cystic Fibrosis?
NCT00996424	PHASE4	TERMINATED	The Effect of Inhaled N-Acetylcysteine Compared to Normal Saline on Sputum Rheology and Lung Function
NCT01044719	PHASE4	UNKNOWN	Duration of Antibiotics in Infective Exacerbations of Cystic Fibrosis
NCT01100606	PHASE4	COMPLETED	A Study to Evaluate the Mode of Administration and Safety of EUR-1008 (APT-1008) in Infants 1 to 12 Months of Age
NCT01131507	PHASE4	COMPLETED	PR-018: An Open-Label, Safety Extension of Study PR-011
NCT01207245	PHASE4	COMPLETED	Circadian Rhythm In Tobramycin Elimination In Cystic Fibrosis
NCT01323101	PHASE4	COMPLETED	Doxycycline Effects on Inflammation in Cystic Fibrosis
NCT01327703	PHASE4	COMPLETED	Control of Steatorrhea in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency
NCT01377792	PHASE4	COMPLETED	Study of Long-term Treatment With Hypertonic Saline in Patients With Cystic Fibrosis
NCT01400750	PHASE4	COMPLETED	Comparison of 2 Treatment Regimens for Eradication of P Aeruginosa Infection in Children With Cystic Fibrosis
NCT01429259	PHASE4	COMPLETED	Population Pharmacokinetics of Prolonged Infusion Meropenem in Cystic Fibrosis (CF) Children
NCT01608555	PHASE4	COMPLETED	Tobramycin 300 mg Once-a-day (o.d.) Aerosol in Adults With Cystic Fibrosis
NCT01667094	PHASE4	UNKNOWN	A Study Comparing Continuous Infusion Antibiotics to Standard Treatment for Lung Infections in Cystic Fibrosis
NCT01694069	PHASE4	TERMINATED	Continuous Infusion Piperacillin-tazobactam for the Treatment of Cystic Fibrosis
NCT01702415	PHASE4	WITHDRAWN	Zoledronic Acid in Cystic Fibrosis
NCT01712334	PHASE4	COMPLETED	A Study of the Comparable Efficacy and Safety of Pulmozyme (Dornase Alfa) Delivered by the eRapid Nebulizer System in Patients With Cystic Fibrosis
NCT01737983	PHASE4	COMPLETED	Effect of Lactobacillus Reuteri in Cystic Fibrosis
NCT01844778	PHASE4	COMPLETED	Ease of Use and Microbial Contamination of Tobramycin Inhalation Powder (TIP) Versus Nebulised Tobramycin Inhalation Solution (TIS) and Nebulised Colistimethate (COLI)
NCT01880346	PHASE4	COMPLETED	Comparison of Absorption of Vitamin D in Cystic Fibrosis
NCT01882400	PHASE4	COMPLETED	Assessment of Response to Treatment of Osteoporosis With Oral Bisphosphonates in Patients With Muscular Dystrophy
NCT01937325	PHASE4	UNKNOWN	CPET in CF Patients With One G551D Mutation Taking VX770
NCT02015663	PHASE4	TERMINATED	Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles
NCT02048592	PHASE4	UNKNOWN	Impact of Immunonutrition on the Patients With Cystic Fibrosis